ICS 2017 Scientific Podium Short Oral Session S2 - Lower Urinary Tract and Therapeutics

Speakers
	Scientific Podium Short Oral Session S2
	Wednesday 13th September 2017
	09:00 - 10:30
	Cavaniglia B Capacity: 400
	Lunch provided
S Sherif Mourad ICS Chair S Sergio Serni ICS Chair
Professional interest
Urology

09:00

#7 Prevalence of LUTS in Brazil: an epidemiological study

Presenter: Cristiano Gomes

Soler R¹, Gomes C², Averbeck M³, Koyama M⁴
1. Astellas Pharma Brazil, Avenida Nações Unidas 14171 – 4 andar, São Paulo, Brazil, 2. University of São Paulo School of Medicine, Avenida Dr. Eneas de Carvalho Aguiar, 255, Sala 710F, 7º. Andar, CEP 05403-000 São Paulo – SP, Brazil, 3. Urology Department, Moinhos de Vento Hospital, Video Urodynamics Unit, Rua Tiradentes, 333, Porto Alegre, RS, 90560-030, Brazil, 4. Kamiyama Statistical Consulting, Avenida Dr. Altino Arantes, 975 casa 4, CEP 04042-034, Sâo Paulo – SP, Brazil
Voiding Dysfunction , Questionnaire, Quality of Life (QoL)

09:07

#8 Therapeutic adding effect of mirabegron 50 mg in Asian OAB patients after initial treatment of mirabegron 25 mg – a randomized clinical trial

Presenter: Chun-Hou Liao

Liao C¹, Wu S², Jiang Y², Kuo H²
1. Department of Urology, Cardinal Tien Hospital and School of Medicine, Fu-Jen Catholic University, New Taipei City, Taiwan, 2. Department of Urology, Buddhist Tzu Chi General Hospital and Tzu Chi University, Hualien, Taiwan
Overactive Bladder, Incontinence, Imaging

09:15

#9 Long-term anticholinergic add-on therapy in overactive bladder (OAB) patients refractory to mirabegron monotherapy: a multicentre, randomized study (MILAI II study)

Presenter: Osamu Yamaguchi

Yamaguchi O¹, Kakizaki H², Homma Y³, Igawa Y⁴, Takeda M⁵, Nishizawa O⁶, Gotoh M⁷, Yoshida M⁸, Yokoyama O⁹, Seki N¹⁰, Hamada T¹¹, Kuroishi K¹¹
1. Division of Bioengineering and LUTD Research, Nihon University, School of Engineering, Koriyama, Japan, 2. Department of Urology, Asahikawa Medical University, Asahikawa, Japan, 3. Department of Urology, The University of Tokyo Graduate School of Medicine, Tokyo, Japan, 4. Department of Continence Medicine, The University of Tokyo Graduate School of Medicine, Tokyo, Japan, 5. Department of Urology, Division of Clinical Medicine, Graduate Faculty of Interdisciplinary Research, University of Yamanashi, Chuo, Japan, 6. Department of Urology, North Alps Medical Center Azumi Hospital, Kitaazumi, Japan, 7. Department of Urology, Nagoya University Graduate School of Medicine, Nagoya, Japan, 8. Department of Urology, National Center for Geriatrics and Gerontology, Obu, Aichi, Japan, 9. Department of Urology, University of Fukui Faculty of Medical Sciences, Fukui, Japan, 10. Department of Urology, Kyushu Central Hospital of the Mutual Aid Association of Public School Teachers, Fukuoka, Japan, 11. Astellas Pharma Inc, Tokyo, Japan
Overactive Bladder, Incontinence, Urgency/Frequency

09:22

#10 How durable is the effect of Mirabegron in successfully treated OAB patients? Secondary analysis of multicentre study

Presenter: Kamil Svabik

Svabik K¹, Masata J¹, Krhut J², Zachoval R³, Hanus T⁴, Horcicka L⁵, Martan A¹
1. Ob/Gyn Dept, First Faculty of Medicine, Charles University, General University Hospital in Prague, 2. Dept. of Urology, University Hospital Ostrava, 3. Dept. of Urology, Thomayer Hospital Prague, 4. Dept. of Urology, First Faculty of Medicine, Charles University, General University Hospital in Prague, 5. GONA clinic Prague
Overactive Bladder, Pharmacology, Urgency/Frequency

09:30

#11 Effect of β3-adrenergic receptor agonist administration on Blood Pressure in the Elderly

Presenter: Yuichiro Nakamura

Nakamura Y¹, Matsuo T¹, Araki K¹, Yasuda T¹, Sagara Y¹, Ohba K¹, Miyata Y¹, Sakai H¹
1. Nagasaki University Hospital
Overactive Bladder, Pharmacology, Gerontology

09:37

#12 Does mirabegron treatment affect the mental status of treatment-naïve female patients with overactive bladder?

Presenter: Manami Kinjo

Kinjo M¹, Okegawa T¹, Nutahara K¹
1. Kyorin Univerity Scool of Medicine
Female, Overactive Bladder, Pharmacology

09:45

#13 Long-term outcomes of mirabegrone in the treatment of overactive bladder in different age groups of patients – results of Miracle II study

Presenter: Roman Zachoval

Zachoval R¹, Martan A², Krhut J³, Hanus T⁴, Svabik K², Horcicka L⁵, Halaska M⁶
1. Department of Urology, Thomayer Hospital and First and Third Faculty of Medicine, Charles University, Prague, Czech Republic, 2. Clinic of Gynecology and Obstetrics, General University Hospital and First Faculty of Medicine, Charles University, Prague, Czech Republic, 3. Department of Urology, University Hospital Ostrava, Czech Republic, 4. Clinic of Urology, General University Hospital and First Faculty of Medicine, Charles University, Prague, Czech Republic, 5. Department of Gynecology GONA, 6. Clinic of Gynecology and Obstetrics, Hospital Na Bulovce and First Faculty of Medicine, Charles University, Prague, Czech Republic
Conservative Treatment, Overactive Bladder, Prospective Study

09:52

#14 Efficacy and safety of combination of tolterodine and pilocarpine in overactive bladder patients: A randomized double-blind multicenter phase 3 study

Presenter: Kyu-Sung Lee

Lee K¹, Ko K J¹, Yoon S J², Kim S W³, Kim S⁴, Seo J T⁵, Choo M⁶, Lee S W¹
1. Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, 2. Department of Urology, Gachon University Gil Medical Center, 3. Catholic Integrative Medicine Research Institute, College of Medicine, The Catholic University of Korea, 4. Department of Urology, Chonnam National University Medical School, 5. Department of Urology, Cheil General Hospital Dankook University College of Medicine, 6. Department of Urology, Asan Medical Center, University of Ulsan College of Medicine
Clinical Trial, Overactive Bladder, Pharmacology

10:00

#15 Results of a Phase 1B Multicenter Study Evaluating the Safety and Potential Activity of Two Escalating Doses of hMaxi-K Gene Transfer by Direct Injection into the Bladder Wall in Female Participants with Idiopathic (Non-neurogenic) Overactive Bladder Syndrome and Detrusor Overactivity: Double Blind, Imbalanced Placebo Controlled Design Within 2 Sequential Active Treatment Groups

Presenter: Eric Rovner

Chai T¹, Rovner E², Jacobs S³, Christ G⁴, Andersson K⁵, Efros M⁶, Nitti V⁷, Melman A⁸
1. Yale University, 2. University of South Carolina, 3. Ion Channel Innovations, LLC, 4. Universty of Virginia, 5. WFIRM, Wake Forest University, 6. Accumed Research Associates, 7. NYU Medical Center, 8. Ion Channel Innovations, LLC/Albert Einstein College of Medicine
Overactive Bladder, Urgency Urinary Incontinence, Nocturia, Urgency/Frequency, Prospective Study

10:07

#16 The effects of sildenafil on bladder contractility and neuronal ATP release in the mouse urinary bladder

Presenter: Basu Chakrabarty

Chakrabarty B¹, Ito H¹, Ximenes M², Vahabi B², Pickering T¹, Kanai A³, Drake M¹, Fry C¹
1. University of Bristol, 2. University of West England, 3. University of Pittsburgh
Basic Science, Physiology, Pathophysiology, Overactive Bladder

10:15

#17 TRIGONAL DENERVATION BY SELECTIVE RADIOFREQUENCY ABLATION FOR THE TREATMENT OF OAB

Presenter: Le-Mai Tu

Tu L¹, Dmochowski R², Robert M³, Everaert K⁴, Rovner E⁵, De Wachter S⁶
1. Sherbrooke University Hospital, 2. Vanderbilt University, 3. University of Calgary, 4. University Ghent, 5. Medical University of South Carolina, 6. University Antwerp
Clinical Trial, Female, Overactive Bladder, Urgency Urinary Incontinence

10:22

#18 Generating new evidence of effectiveness of Percutaneous Tibial Nerve Stimulation (PTNS) and Sacral Nerve Stimulation (SNS) through effective utilisation of audit data.

Presenter: Colette Anderson

Anderson C¹, Whittaker V², Khunda A³, Ballard P³
1. South Tees NHS Trust,, 2. University of Teesside, 3. South Tees NHS Trust
Neuromodulation, Female, Overactive Bladder, Voiding Diary, Retrospective Study

Content Visitors (staff only)

Lower Urinary Tract and Therapeutics

Session Schedule

Comments

Chat